ABVX (Abivax) Common Stock : $0.69 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Abivax Common Stock?

Abivax's quarterly common stock increased from Dec. 2022 ($0.24 Mil) to Jun. 2023 ($0.46 Mil) and increased from Jun. 2023 ($0.46 Mil) to Dec. 2023 ($0.69 Mil).

Abivax's annual common stock increased from Dec. 2021 ($0.19 Mil) to Dec. 2022 ($0.24 Mil) and increased from Dec. 2022 ($0.24 Mil) to Dec. 2023 ($0.69 Mil).

Abivax Common Stock Historical Data

The historical data trend for Abivax's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Common Stock Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.14

0.17

0.19

0.24

0.69

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															0.19	0.18	0.24	0.46	0.69

Abivax Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (NAS:ABVX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.